Clinical trial
A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19
NCT04379271 is registered in ClinicalTrials.gov with Immunic AG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19
- Lead sponsor
- Immunic AG
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- June 11, 2020
- Completion date
- February 23, 2021
- Enrollment
- 234 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.